CERo Therapeutics Holdings, Inc. (CERO)

CERo Therapeutics Holdings, Inc. was a clinical-stage biotechnology company headquartered in South San Francisco, California. It developed engineered T cell therapies for cancer using a platform called Chimeric Engulfment Receptor technology, designed to direct T cells to engulf and destroy tumor cells in a way that mimics how the immune system clears dying cells.

The lead program targeted an eat-me signal that is highly expressed on certain B cell and myeloid tumors, with the aim of improving recognition and elimination of cancer cells by engineered T cells. The company focused on hematologic malignancies and other cancers and sought collaborations with academic institutions and other partners to advance its research.

CERo became a public company in February 2024 through a business combination with Phoenix Biotech Acquisition Corp., a special purpose acquisition company. After the transaction, the combined company's common stock traded on the Nasdaq Capital Market under the symbol CERO. As a pre-revenue company, CERo depended on equity financings to fund its research and development.

In 2025 the company ran into listing difficulties. On August 28, 2025 it was notified of a Nasdaq Staff determination that it no longer met Listing Rule 5550(b)(1). CERo appealed to a Listing Qualifications Hearings Panel on September 3, and a hearing was held on October 14, 2025.

On October 29, 2025 the Panel issued a decision to suspend the company's securities. CERo appealed that decision the same day, but the appeal did not stay the suspension, and trading in its common stock was suspended on October 31, 2025. The Staff delisting determination became final in December 2025.

The Nasdaq Listing and Hearing Review Council upheld the Panel's decision on January 29, 2026, and the Nasdaq Board issued a final action letter on February 6, 2026 stating that it would not call the matter for review.

With the appeals concluded, Nasdaq issued its formal delisting determination on July 10, 2026 and filed a Form 25 with the SEC. The removal of CERo's common stock from listing and registration on Nasdaq took effect at the opening of trading on July 23, 2026. The delisting was not connected to an acquisition or bankruptcy.